VEEV logo

Veeva Systems Inc.

VEEV · What the business does, what can go wrong, and how options sellers approach it

What it does

Veeva Systems builds cloud-based software for the life sciences industry, including pharmaceutical, biotechnology and medical device companies. Its products help these companies manage customer relationships, clinical trials, regulatory filings, quality processes and product content.

Two product families are central. Its customer relationship management software helps sales and medical teams manage interactions with doctors and other healthcare professionals. Veeva Vault is a content and data platform used for functions such as clinical, regulatory, quality and commercial work.

How it makes money

Veeva sells software mostly through subscriptions. Customers pay recurring fees to use its applications, often under multi-year relationships. The company also earns revenue from professional services, such as implementation and training, and from data products that support commercial teams.

Because the software is built for one industry, Veeva can tailor it to strict regulatory needs, which can make it hard for customers to replace once embedded in daily operations.

Why investors own it

Investors are typically drawn to its recurring revenue, its focus on a specialized industry with demanding compliance requirements, and the switching costs that come from deep integration into customer workflows. The business has historically been profitable and has not needed heavy borrowing. Some investors also like that it can add new products to an existing customer base.

What can go wrong

  • Customer concentration in one industry means pharma budget cuts or industry consolidation can slow demand.
  • Competitors, including large enterprise software firms, could target its markets more aggressively.
  • Changes in its relationships with data providers or with key partners could affect certain products.
  • Regulatory shifts in healthcare or data privacy can raise costs or limit how products are used.
  • A premium valuation, if it applies, can make the stock sensitive to any slowdown in growth.

What to watch

  • Subscription revenue growth and customer retention
  • Adoption of Vault applications beyond the core products
  • Progress of its CRM offering with large customers
  • Operating margin trends
  • Spending trends at pharmaceutical and biotech customers

Options income angle

Options on VEEV are generally available across multiple expirations, with liquidity usually best in near-term, at-the-money contracts. Bid-ask spreads can be wider than on the largest mega-cap names.

Implied volatility tends to rise ahead of quarterly earnings reports and during broad swings in software or growth stocks.

One caution for premium sellers: earnings reactions can produce large gaps in price, which may move the stock well beyond a sold strike overnight.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended January 31, 2026, filed March 20, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Veeva reported growth in revenue and profit for the fiscal year ended January 31, 2026, with total revenues of $3,195 million and net income of $909 million. The filing also centers on a major transition: the company is moving its CRM (customer relationship management) customers off the Salesforce platform onto its own Vault CRM, while Salesforce competes for those same customers.

How the business did

  • Total revenues were $3,195 million versus $2,747 million a year earlier, up 16%. Subscription revenues were $2,684 million, up 17%. Of the $449 million revenue increase, $400 million came from subscriptions.
  • R&D and Quality Solutions added $247 million of subscription revenue and Commercial Solutions added $153 million. Management credited existing customers using more products, plus annual inflation-linked price increases.
  • Net income was $909 million versus $714 million. Other income, net rose $50 million, mainly from interest on higher investment and cash balances. The effective tax rate rose to 23.9% from 22.3%, partly because of the One Big Beautiful Bill Act.
  • General and administrative expenses rose $35 million, mainly from a net $26 million increase in litigation settlement-related charges.
  • Operating cash flow was $1,415 million versus $1,090 million. Cash, cash equivalents and short-term investments totaled $6.6 billion. The company repurchased and retired 801,735 shares for approximately $180 million.

Risks specific to this company

  • Salesforce dependency: Veeva CRM runs on Salesforce's platform. The agreement expired September 1, 2025. Until September 1, 2030, Veeva may not sell Salesforce-based applications to new customers, and sales to existing customers may not exceed 150% of their seats in use at September 1, 2025. Salesforce can end the wind-down period early in certain circumstances.
  • CRM competition and migration: Salesforce has announced that certain large Veeva CRM customers committed to its CRM, and a number of customers have told Veeva they intend to move. Veeva CRM is supported until December 31, 2029, and migration to Vault CRM could cause outages or disruption.
  • Customer concentration: The top 10 customers accounted for 28% of total revenues in each of the last three fiscal years. Larger customers are expected to push harder on pricing at renewal.
  • Life sciences exposure: Nearly all sales go to life sciences companies. Drug pricing rules, cuts to agency funding, industry mergers and limits on direct-to-consumer drug advertising (which could hurt the Crossix business) could reduce demand.
  • Short contracts and cancellation rights: Most subscriptions run one year. Multi-year agreements generally let customers terminate for convenience. Under the EU Data Act, effective September 12, 2025, EU customers may cancel without cause.
  • International exposure: Customers outside North America were approximately 40% of total revenues. The filing cites sanctions affecting Russia, operations in Israel and currency swings.

What management is watching

  • Management expects R&D and Quality Solutions to rise as a share of subscription and total revenues.
  • Costs are expected to keep rising: cost of subscription (usage and data investment), cost of professional services, R&D, and sales and marketing, mostly from employee compensation. General and administrative expenses are expected to fall next fiscal year because of the litigation settlement charges.
  • Spending is flagged for Veeva AI (including large language model costs) and for data acquisition tied to Veeva Compass.
  • The OBBBA is expected to increase operating cash flows in future periods, though management cannot estimate the amount.
  • Management points to non-GAAP measures, which strip out items such as stock-based compensation, amortization of purchased intangibles and litigation settlement-related charges. Diluted net income per share was $5.44 on a GAAP basis and $8.10 non-GAAP. Management also calls its full-year subscription revenue and normalized billings guidance the best indicators of momentum. Normalized billings adjust for renewal-date and billing-frequency changes.
  • A $2 billion share repurchase program was authorized in January 2026 with a two-year term, funded from working capital.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended July 31, 2026, filed August 27, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Veeva grew total revenues 18% in the quarter ended July 31, 2026, and profit grew faster than sales. Diluted earnings per share were $1.66 versus $1.19 a year earlier, helped by a prior-year litigation charge that did not repeat. The report also shows some customers moving away from legacy Veeva CRM, with some choosing a competitor.

How the business did

  • Revenue: Subscription revenues rose 16% and professional services and other revenues rose 24%. For six months, total revenues rose 17%. Of the quarter's subscription increase, $68 million came from R&D and Quality Solutions and $40 million from Commercial Solutions. The company credited expanding use by existing customers and its annual inflation price adjustment.
  • Margins and costs: Total gross margin was 75% in both quarters. Most cost growth was employee pay and headcount. General and administrative expense fell 26% because the prior-year quarter included $31 million of litigation settlement-related charges.
  • Earnings: Non-GAAP diluted earnings per share, which exclude items such as stock-based pay, were $2.35 versus $1.99. The effective tax rate fell to 21.8% from 24.5%, mainly due to a larger FDDEI deduction (a tax break on certain foreign-derived income) under the OBBBA tax law.
  • Cash and capital return: Operating cash flow for six months was $1,366 million versus $1,116 million. Cash, cash equivalents and short-term investments totaled $7.2 billion. The company repurchased 2,663,443 shares for approximately $467 million under a $2 billion program authorized in January 2026. It also acquired Rise Healthcare Tech, Inc. ("Ostro").

What management is watching

  • Management expects R&D and Quality Solutions to grow as a share of subscription and total revenues. That group made up 54% of subscription revenues for the six months.
  • The first fiscal quarter is the strongest for cash collections, so operating cash flow is expected to be substantially less in each later quarter. The OBBBA is expected to keep reducing cash taxes for the rest of the fiscal year, though the company cannot estimate the amount.
  • Cost pressure comes from computing infrastructure, data costs tied to investment in data solutions, and hiring.

New or changed risks

  • CRM competition and migration: Salesforce has announced that certain large Veeva CRM customers committed to its CRM, and a number of customers told the company they intend to move. Veeva CRM will be supported until December 31, 2029.
  • Salesforce platform wind-down: Under the agreement's wind-down period from September 1, 2025 to September 1, 2030, the company cannot sell Salesforce-based applications to new customers. After September 1, 2030, it cannot sell them to any customers.
  • AI dependence: Veeva AI products rely on large language models from third parties. The filing warns that access to some frontier AI models could be suspended or restricted by providers or by governments.
  • EU Data Act: In effect since September 12, 2025, it lets EU customers cancel subscriptions without cause after notice and a transition period.

Follow VEEV in Kortex

The Kortex app shows VEEV's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.